phase 1_completion
saveAkeso Inc — ebronucimab (Phase I Trial Completion)
community read0 votes
Therapy area: Metabolic Disorders. Indication: Heterozygous Familial Hypercholesterolemia (heFH), Hypercholesterolemia, Mixed Dyslipidemia
Data sources
globaldata
Found something off?
comments(0)
5-min edit window · permanent after that